Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × vistusertib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 DLBCL 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1

Interventions

Rituximab 57 Cyclophosphamide 34 fludarabine 20 Bendamustine Hydrochloride 20 pembrolizumab 18 Brentuximab Vedotin 18 Gemcitabine 17 Prednisone 16 Doxorubicin 16 ibrutinib 15 obinutuzumab 14 Vincristine 13 Nivolumab 9 Lenalidomide 9 parsaclisib 7 atezolizumab 7 Rifampin 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 duvelisib 6 Vorinostat 6 MLN 8237 6 venetoclax 5 Etoposide 5 zanubrutinib 4 rasburicase 4 ixazomib 4 idelalisib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡